-
T656597-1ml(Rac)-Tavapadon ((Rac)-PF-06649751) is a potent and selective noncatechol dopamine D1 receptor agonist. (Rac)-Tavapadon displays potent full agonism in the GS activation assay as well as partial agonism in the β-arrestin2 recruitment assay (GS-cAMP,
-
U647938-10mg(Rac)-Upacicalcet is the racemate of Upacicalcet.Upacicalcet is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels, by acting directly on parathyroid cell
-
U647938-5mg(Rac)-Upacicalcet is the racemate of Upacicalcet.Upacicalcet is an intravenous calcimimetic agent. Upacicalcet suppresses excessive parathyroid hormone (PTH) secretion, thereby lowering blood PTH levels, by acting directly on parathyroid cell
-
W649483-10mg(Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT 2C receptor agonist with a K i of 4 nM and an EC 50 of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT 2C than 5-HT 2A and 5-HT 2B receptors. (Rac)-WAY-161503 has anti-obesity
-
W649483-5mg(Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT 2C receptor agonist with a K i of 4 nM and an EC 50 of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT 2C than 5-HT 2A and 5-HT 2B receptors. (Rac)-WAY-161503 has anti-obesity
-
W655879-1ml(Rac)-WAY-161503 is a potent, selective, highly affinity 5-HT 2C receptor agonist with a K i of 4 nM and an EC 50 of 12 nM. (Rac)-WAY-161503 displays higher affinity for 5-HT 2C than 5-HT 2A and 5-HT 2B receptors. (Rac)-WAY-161503 has anti-obesity
-
C412593-100mgInformationCPD77 (MUN91789) is a potent inhibitor of SARS-CoV-2 main protease.
-
C412593-10mgInformationCPD77 (MUN91789) is a potent inhibitor of SARS-CoV-2 main protease.
-
C412593-25mgInformationCPD77 (MUN91789) is a potent inhibitor of SARS-CoV-2 main protease.
-
C412593-50mgInformationCPD77 (MUN91789) is a potent inhibitor of SARS-CoV-2 main protease.
-
C412593-5mgInformationCPD77 (MUN91789) is a potent inhibitor of SARS-CoV-2 main protease.
-
Z647219-10mg(Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB 1 R)/iNOS antagonist, with a K i of 5.7 nM for CB 1 R. (Rac)-Zevaquenabant is potential for the research of liver fibrosisForm:SolidIC50&: Target:CB 1 R/iNOS.